218916-51-9 Usage
Uses
Used in Pharmaceutical Industry:
Euphorbiafactor L2 is used as a potential anti-tumor agent for its studied biological effects. euphorbiafactor L2's potential to exhibit anti-tumor activity makes it a candidate for further research and development in the pharmaceutical industry, with the aim of harnessing its properties for cancer treatment.
Used in Research Applications:
Euphorbiafactor L2 is used as a subject of study for its potential biological effects. Researchers are interested in understanding the compound's interactions with biological systems and its potential applications in medicine, particularly in the context of anti-tumor activity. This research could lead to the discovery of new therapeutic approaches and contribute to the advancement of medical science.
Check Digit Verification of cas no
The CAS Registry Mumber 218916-51-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,8,9,1 and 6 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 218916-51:
(8*2)+(7*1)+(6*8)+(5*9)+(4*1)+(3*6)+(2*5)+(1*1)=149
149 % 10 = 9
So 218916-51-9 is a valid CAS Registry Number.
218916-51-9Relevant academic research and scientific papers
Wang, Wang,Wu, Yanli,Li, Chen,Yang, Yueying,Li, Xingzhou,Li, Hua,Chen, Lixia
, (2020)
Euphorbia factor L3, a lathyrane diterpenoid extracted from Euphorbia lathyris, was found to display good anti-inflammatory activity with very low cytotoxicity. To find more potent anti-inflammatory drugs, two series of Euphorbia factor L3 derivatives with fatty and aromatic acids were designed and synthesized. Among them, lathyrane derivative 5n exhibited most potent inhibition on LPS-induced NO production in RAW264.7 cells with no obvious cytotoxicity. To determine the key characteristics of Euphorbia factor L3 derivatives that contribute to anti-inflammatory activity, we conducted a structure-activity relationship study of these compounds.
